Immunization

The COVID-19 pandemic disrupted routine immunization programs around the world.

Confidence in vaccines is lower post-pandemic across all demographic groups

Addressing hesitancy is more than just offering pertinent information.

In a recent study, researchers found that text message reminders led to increased influenza vaccination rates, along with many receiving the vaccine sooner.

Human papillomavirus vaccines can help prevent cancer, but uptake still lags.

Phase I/II data indicate that new investigative pneumococcal conjugate vaccine shows efficacy in preventing disease in adults.

Offering immunization services at the pharmacy promotes public health and strengthens patient-pharmacy staff relationships.

Results of multiple studies were presented at IDWeek 2022.

After multiple approvals and emergency use authorizations, It’s time to take stock of the state of pediatric COVID-19 vaccines.

Adult vaccine uptake lags and understanding the reasons could be important.

The US was the first country to begin universal vaccination of children against varicella.

As vaccine hesitancy grows, fewer children are receiving routine childhood vaccines.

A selection of the latest COVID-19 vaccine research out of IDWeek 2022.

What does the uptake look like for one of the most common vaccines given during pregnancy—and what does this mean for the future?

Adults who receive influenza and pneumococcal vaccines may be more likely to receive COVID-19 vaccines and boosters.

Pharmacists can play a key role in helping to improve backsliding vaccination rates.

Infants of fully vaccinated mothers had fewer cases of hospitalization from COVID-19 than those unvaccinated.

William J. Muller, MD, PhD, discusses COVID-19 vaccinations for children of all ages and describes what is on the horizon for RSV.

When it comes to the COVID-19 vaccine, independent pharmacies are being set up to fail by federal health partners.

This National Immunization Awareness Month, prepare your pharmacy to offer important vaccines.

Pfizer-BioNTech hopes booster can be available for use this fall.

A panel of experts open a discussion surrounding influenza vaccines amid patient vaccine hesitancy.

Domestic production to begin at Michigan-based pharmaceutical maker.

The FDA has granted Emergency Use Authorization EUA of the Jynneos vaccine for pediatric patients <18 years who are at high risk of monkeypox infection.

The latest guidance for when to administer the COVID-19 vaccine to patients aged 6 months and older.

Adults aged 18 and older are eligible to receive the vaccine.

Purchase follows FDA recommendation to include Omicron component in boosters.

The preferential recommendation is built on research and real-world data

The FDA approved the pneumococcal 15-valent conjugate vaccine for the prevention of invasive pneumococcal disease in infants and children.

The FDA announced the EUA of both Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children aged 6 months and older.